Company intelligence / Profile preview

FORMEL Skin

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

FORMEL Skin has demonstrated rapid growth since its launch in June 2020. The company has delivered over 150,000 treatments to patients in Germany and Switzerland. Its digital-first approach enables faster access to personalized medical care for chronic skin conditions with high patient engagement and satisfaction. No clinical trial data published; outcomes are based on real-world use and customer feedback.

Therapeutic areas: Dermatology
Modalities: Small moleculeNon-pharmacological therapyBiologic
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

personalized dermatological formulations

Commercial

Indications: Acne, Rosacea, Melasma

Partnerships

Cherry VenturesHeartcore CapitalSingular VC

Beyond the preview

Go deeper on FORMEL Skin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FORMEL Skin.

Explore the full profile